Search clinical trials for: Rivaroxaban

Total 533 results

Genuine Research Center, Egypt
Horus for Pharmaceutical Industries, Egypt

Completed

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

Healthy

Egypt
Second Affiliated Hospital, School of Medicine,...

Unknown

DUAL Antithrombotic Therapy in Patients With AF and ACS

Atrial Fibrillation | Acute Coronary Syndromes
Northwestern University

Completed

Tolerance of Chlorhexidine Gluconate Vaginal Cleansing Solution

Surgical Preparation of the Vagina

United States
Boehringer Ingelheim
Health ResearchTx, LLC (HRTX); inVentiv Health Clinical (iVH); United States...

Completed

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

Atrial Fibrillation

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

Non-valvular Atrial Fibrillation (NVAF)

Japan
Janssen Research & Development, LLC
Bayer

Completed

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF)

Coronary Artery Disease | Heart Failure

United States, France, Poland, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Mexico, Portugal, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Japan, Canada, Netherlands, Den... and more
Drug Safety Research Unit, Southampton, UK

Completed

Rivaroxaban ACS Specialist Cohort Event Monitoring Study (ROSE ACS)

Acute Coronary Syndrome

United Kingdom
Bayer
Janssen Research & Development, LLC

Completed

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

Thrombosis

Canada, United States, Belgium, Spain, Italy, France, Finland, Hungary
Capital Medical University

Completed

Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

Neoplasms

China
Bayer

Completed

Accessibility to New Drugs Versus SOC in Sweden

Anticoagulation

Sweden
Peking University First Hospital
Bayer

Unknown

Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension

Hypertension

China
Boehringer Ingelheim

Completed

Medical Need of OAC Reversal

Atrial Fibrillation

Japan
Bristol-Myers Squibb

Completed

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

Atrial Fibrillation
Onze Lieve Vrouw Hospital

Completed

Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients

Vascular Calcification

Belgium
Ostfold Hospital Trust

Completed

Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study (Ri-Schedule)

Deep Venous Thrombosis

Norway
Swiss Paraplegic Centre Nottwil

Withdrawn

Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury (rivaroxaban)

Thromboembolism | Spinal Cord Injuries

Switzerland
Yonsei University

Unknown

Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

Acute Heart Failure

Korea, Republic of
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Terminated

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) (NAVIGATE ESUS)

Stroke

Denmark, France, Spain, China, United States, Switzerland, Germany, Greece, Korea, Republic of, Portugal, Japan, Israel, Canada, Australia, Turkey, Russian Federation, Sweden, Austria, Czechia, Poland, United Kingdom, Belgium, Brazil, Hungar... and more
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (X-PRESS)

Atrial Fibrillation

Taiwan
Centre Hospitalier Universitaire de Saint Etienne
Bayer

Terminated

PROphylaxis in NOn Major Orthopaedic Surgery (PRONOMOS)

Non-major Orthopaedic Surgery

France
McMaster University
Bayer

Completed

Rivaroxaban Anticoagulation for Superficial Vein Thrombosis (RASET)

Symptomatic Superficial Vein Thrombosis

Canada
Walter Ageno

Unknown

Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis (RIDTS)

Deep Vein Thrombosis

Italy
Università degli Studi dell'Insubria
Ottawa Hospital Research Institute

Unknown

Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study

Portal Vein Thrombosis | Mesenteric Vein Thrombosis | Splenic Vein Thrombosis

Canada, Italy
Isfahan University of Medical Sciences

Unknown

Efficacy Comparison of Warfarin Versus Rivaroxaban CVT

Cerebral Venous Thrombosis

Iran, Islamic Republic of
Janssen Scientific Affairs, LLC

Completed

Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation

Atrial Fibrillation

United States
Hospital do Servidor Publico Estadual

Unknown

Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs. (DVT)

Deep Venous Thrombosis

Brazil
Susan Smyth
Janssen Scientific Affairs, LLC

Terminated

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis (XENITH)

Venous Thrombosis | Pulmonary Embolism
PharmEvo Pvt Ltd

Withdrawn

Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin

Atrial Fibrillation | Mitral Valve Stenosis

Pakistan
Bayer
Janssen Research & Development, LLC

Completed

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Venous Thromboembolism

United States
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis (EINSTEINJr)

Venous Thromboembolism

Switzerland, Spain, United States, Austria, Italy, Russian Federation, United Kingdom, Brazil, Australia, Canada, Hungary, Netherlands, Israel, Poland, Japan
Assistance Publique - Hôpitaux de Paris
Bayer

Completed

Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban (CASTA-DIVA)

Venous Thromboembolism | Neoplasm

France
Fundació Institut de Recerca de l'Hospital de la...

Completed

Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance (HERO)

Ischemic Stroke

Spain, Italy
Fundación para la Investigación del Hospital Clínico...

Completed

Periprocedural Direct Oral Anticoagulant Management (RA-ACOD)

Periprocedural Complication

Spain
Centro Hospitalar e Universitário de Coimbra, E...

Unknown

Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets (SCOOP)

Coronary Artery Disease | Saphenous Vein Graft Patency

Portugal
Centre Hospitalier Universitaire de Besancon
Etablissement Français du Sang

Completed

Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events (Pgp NACO)

Hemorrhage | Thromboembolism | Anticoagulants

France
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates (Einstein Jr)

Thromboembolism

Spain, Austria, Israel, Italy, France, Turkey, Germany
Christian Torp-Pedersen
Odense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University Hospital

Unknown

Rivaroxaban or Aspirin for Biological Aortic Prosthesis

Thrombosis | Aortic Stenosis | Aortic Regurgitation

Denmark
Martini Hospital Groningen

Completed

Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery (DARINA)

Venous Thromboembolism

Netherlands
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department (MERCURY PE)

Pulmonary Embolism

United States
Hospital Universitari Vall d'Hebron Research Institute

Completed

Rivaroxaban for Patients With Antiphospholipid Syndrome

Antiphospholipid Syndrome

Spain
David Garcia Cinca
IDIBAPS - Dr. Juan Carlos García Pagán

Unknown

Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis (CIRROXABAN)

Cirrhosis

Spain
Hanoi Medical University
Bach Mai Hospital

Unknown

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching

Thrombosis | Deep Vein Thrombosis | Surgery--Complications

Vietnam
Seoul National University Hospital

Completed

Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel

Acute Coronary Syndrome | Acute Myocardial Infarction | Unstable Angina

Korea, Republic of
Hospital Ana Nery
Federal University of Bahia

No longer available

Rivaroxaban in Mechanical Valves: RMV Study (RMV)

Prosthesis; Cardiac, Heart, Functional Disturbance as Result
Bayer
Janssen Research & Development, LLC

Completed

Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

Atrial Fibrillation

Spain
Fertilitetscentrum AB
Vitrolife

Completed

Comparisons of Human Embryonic Development Using Single Medium With and Without the Addition of Antioxidants

Blastocyst | Human | Antioxidants | Culture Media | Embryo

Sweden
Bayer

Completed

Atrial Fibrillation Patient Preference Study (PRiSMA-AF)

Atrial Fibrillation

Sweden
University of Padova

Terminated

Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS)

Antiphospholipid Syndrome

Italy
Professor Saad Shakir
Bayer

Completed

An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®). (ROSE)

Atrial Fibrillation | Deep Vein Thrombosis | Pulmonary Embolism

United Kingdom
David Anderson
Canadian Institutes of Health Research (CIHR)

Completed

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)

Venous Thromboembolism

Canada

Search clinical trials for: Rivaroxaban

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations